Polycythemia Vera Grand Rounds References and Footnotes

Slide 3

Slide 5

Slide 6

Slide 7

Slide 8

Slide 10

Slide 11


1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revisions to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.

2. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680-692.

3. Parasuraman S, DiBonaventura M, Reith K, et al. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Experimental Hematology Oncology. 2016;5:3.

4. Mascarenhas J. A concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms. Clinical Lymphoma, Myeloma & Leukemia. 2016;16 suppl:S124-S129.

5. Spivak JL, Considine M, Williams DM, et al. Two clinical phenotypes in polycythemia vera. The New England Journal of Medicine. 2014;371(9):808-817.

6. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. The British Journal of Haematology. 2010;148(6):961-963.

7. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. The New England Journal of Medicine. 2013;368(1):22-33.

8. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560-561.

9. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total sym